Meta-analysis of the Efficacy and Safety of Edaravone Dexborneol in the Treatment of Cerebral Infarction

The purpose is to evaluate the efficacy and safety of edaravone dexborneol in treating cerebral infarction. Methods: Computer searches were conducted on databases such as PubMed, Cochrane Library, and Web of Science to identify randomized controlled trials of edaravone dexborneol in treating cerebral infarction. Meta-analysis was performed by Review Manager 5.4.1 software on eligible studies. Results: A total of 10 studies meeting the inclusion criteria were included, with a total of 3,324 patients. The Meta-analysis showed that compared to the control group, edaravone dexborneol significantly improved total effective rate, enhanced excellent functional outcomes, and reduced IL-6 levels, with statistically significant differences; however, there were no statistically significant differences in neurological function improvement compared to the control group; in terms of reducing adverse reactions, the control group had a more favorable outcome than edaravone dexborneol, with statistically significant differences. Conclusion: Edaravone dexborneol can significantly improve clinical outcomes in treating cerebral infarction, but may increase the incidence of adverse reactions. Therefore, it is necessary to select appropriate treatment regimens based on clinical circumstances to achieve optimal clinical outcomes.